1Anderson NL, Anderson NG. Proteome and proteomics: new technologies, new concepts and new words. Electrophoresis, 1998,19:1853-1861.
2Unlu M, Morgan M, Minden J, et al. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis, 1997, 18:2071-2077.
3Layh SG, Podtelejnikov A, Mann M, et al. Proteins complexed to the P1 adhesion of mycoplasma pneumoniae. Microbiology, 2000,146:741-747.
4Dayal B, Ertel NH. ProteinChip technology: a new and facile method for the identification and measurement of high-density lipoproteins apoA-I and apoA-II and their glycosylated products in patients with diabetes and cardiovascular disease. J Proteome Res,
5McDonough JL, Neverova I, Van-Eyk JE, et al. Proteomic analysis of human biopsy samples by single two-dimensional electrophoresis: Coomassie, silver, mass spectrometry, and Western blotting. Proteomics, 2002, 2: 978-987.
6Neverova Irina; Van-Eyk JE. Application of reversed phase high performance liquid chromatography for subproteomic analysis of cardiac muscle. Proteomics, 2002, 2: 22-31.
7Taylor SW, Fahy E, Zhang B, et al. Characterization of the human heart mitochondrial proteome. Nat Biotechnol, 2003, 21: 281-286.
8Huber LA, Pfaller K, Vietor I, et al. Organelle proteomics: implications for subcellular fractionation in proteomics. Circ Res, 2003, 92: 962-968.
9Brookes PS, Pinner A, Ramachandran A, et al. High throughput two-dimensional blue-native electrophoresis: a tool for functional proteomics of mitochondria and signaling complexes. Proteomics, 2002, 2: 969-977.
10Taylor SW, Warnock DE, Glenn GM, et al. An alternative strategy to determine the mitochondrial proteome using sucrose gradient fractionation and 1D PAGE on highly purified human heart mitochondria. J Proteome Res, 2002, 1: 451-458.
同被引文献49
1Lucas AL, Korol R, Pepine CJ. Inflammation in atherosclerosis: some thoughts about the acute coronary syndromes [J ]. Circulation, 2006, 113: e728-e732.
2Apple FS, Pearce LA, Chung A, et al. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome [J]. Clin Chem, 2007, 53: 874-81.
3Apple FS, Wu AH, Mair J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome [J ]. Clin Chem, 2005, 51: 810-24.
4Thim T, Hagensen MK, Bentzon JF, et al. From vulnerable plaque to atherothrombosis[J ]. J Intern Med, 2008, 263(5): 506-16.
5Bassand JP, Harem CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes[J]. Eur Heart J, 2007, 28: 1598-660.
6TIM/IIIB investigators effects of tissue plasrninogen activator and comparison of early Invasive and conservative st rategies in unstable angina and Non-Q-wave myocardial infraction. Results of the TIMI IIIB[J]. Circulation, 1994, 89: 1545-56.
7Spacek R,Widimsky P, Straka Z, et al. Value of first day angiography/ angioplasty in evolving non-ST segment elevation myocardial infarction: an open multieenter randomized trial. The V INO Study [J]. Eur Heart J, 2002, 23: 230-8.
8Tousoulis D, Kampoli AM, Stefanadi E, et al. New biochemical markers in acute coronary syndrome[J]. Cttrr Med Chem, 2008, 15: 1288-96.
9Brerman ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain [J]. N Engl J Med, 2003, 349: 1595-604.
10Martin M, Oliver D, Reinhold M, et al. Development of an optimized multimarker strategy for early risk assessment of patients with acute coronary syndromes [ J ]. Clin Chim Acta, 2008, 393:103-9.
